{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:06:59Z","timestamp":1792415219029,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"am","delay-in-days":248,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R43AG044000-01"],"award-info":[{"award-number":["1R43AG044000-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejmech.2021.113666","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T11:23:41Z","timestamp":1624965821000},"page":"113666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis"],"prefix":"10.1016","volume":"224","author":[{"given":"Alison M.","family":"Bendele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Neelagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venugopal","family":"Neelagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-5050","authenticated-orcid":false,"given":"Irving","family":"Sucholeiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2021.113666_bib1","first-page":"1","article-title":"Why is osteoarthritis an age-related disease?","volume":"24","author":"Anderson","year":"2010","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2021.113666_bib2","doi-asserted-by":"crossref","first-page":"16044","DOI":"10.1038\/boneres.2016.44","article-title":"Osteoarthritis: toward a comprehensive understanding of pathological mechanism","volume":"5","author":"Chen","year":"2017","journal-title":"Bone Res"},{"key":"10.1016\/j.ejmech.2021.113666_bib3","series-title":"Stakeholder Insight-Osteoarthritis-Drug Development Lags behind Rising Osteoarthritis Population","year":"2009"},{"issue":"24","key":"10.1016\/j.ejmech.2021.113666_bib4","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2106\/JBJS.N.00743","article-title":"Viscosupplmentation for Osteoarthritis of the knee: a systematic review of the evidence","volume":"97","author":"Jevsevar","year":"2015","journal-title":"J.\u00a0Bone Joint Surg. Am."},{"key":"10.1016\/j.ejmech.2021.113666_bib5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.arth.2014.12.012","article-title":"No difference between intra-articular injection of hyaluronic acid and placebo for mild to moderate knee osteoarthritis: a randomized, controlled, double-blind trial","author":"Van der Weegen","year":"2015","journal-title":"J.\u00a0Arthroplasty"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113666_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.33590\/emj\/10313855","article-title":"Osteoarthritis and ageing","volume":"3","author":"Valdes","year":"2018","journal-title":"European Medical Journal"},{"issue":"2","key":"10.1016\/j.ejmech.2021.113666_bib7","first-page":"204","article-title":"Inflammatory synovitis in degenerative joint disease","volume":"9","author":"Goldenberg","year":"1982","journal-title":"J.\u00a0Rheumatol."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113666_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.joca.2012.11.012","article-title":"Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)","volume":"21","author":"Berenbaum","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"issue":"11","key":"10.1016\/j.ejmech.2021.113666_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrrheum.2010.159","article-title":"The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis","volume":"6","author":"Sellam","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"issue":"18","key":"10.1016\/j.ejmech.2021.113666_bib10","first-page":"1229","article-title":"Synovitis in osteoarthritis: current understanding with therapeutic implications","volume":"19","author":"Mathiessen","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejmech.2021.113666_bib11","doi-asserted-by":"crossref","first-page":"17192","DOI":"10.1073\/pnas.0407788101","article-title":"Critical roles for collagenases-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification","volume":"101","author":"Inada","year":"2004","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"23","key":"10.1016\/j.ejmech.2021.113666_bib12","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1242\/dev.01461","article-title":"Altered endochondral bone development in matrix metalloproteinase 13-deficient mice","volume":"131","author":"Sticken","year":"2004","journal-title":"Development"},{"key":"10.1016\/j.ejmech.2021.113666_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/ard.58.6.357","article-title":"In situ zymographic localization of type II collagen degrading activity in osteoarthritic human articular cartilage","volume":"58","author":"Freemonta","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2021.113666_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/138920108783497659","article-title":"Joint diseases and matrix metalloproteinases: a role for MMP-13","volume":"9","author":"Takaishi","year":"2008","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.ejmech.2021.113666_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.22203\/eCM.v021a16","article-title":"Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in osteoarthritis","volume":"21","author":"Goldring","year":"2011","journal-title":"Eur. Cell. Mater."},{"issue":"R5","key":"10.1016\/j.ejmech.2021.113666_bib16","first-page":"1","article-title":"MMP-13 is a critical target gene during progression of osteoarthritis","volume":"15","author":"Wang","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113666_bib17","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/art.11030","article-title":"Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats","volume":"48","author":"Renkiew","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2021.113666_bib18","first-page":"1912","article-title":"Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM1270 (CGS27023A), in patients with advanced solid cancer","volume":"7","author":"Levitt","year":"2001","journal-title":"Clin. Canc. Res."},{"issue":"11","key":"10.1016\/j.ejmech.2021.113666_bib19","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.joca.2009.04.009","article-title":"OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?","volume":"17","author":"Hellio Le Graverand-Gastineau","year":"2009","journal-title":"Osteoarthritis Cartilage"},{"issue":"984","key":"10.1016\/j.ejmech.2021.113666_bib20","first-page":"1","article-title":"The rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma","volume":"8","author":"Field","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113666_bib21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cardiores.2005.11.032","article-title":"The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors","volume":"69","author":"Peterson","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejmech.2021.113666_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chembiol.2004.11.014","article-title":"Structural basis for a highly selective inhibition of MMP-13","volume":"12","author":"Engle","year":"2005","journal-title":"Chem. Biol."},{"issue":"15\/16","key":"10.1016\/j.ejmech.2021.113666_bib23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.drudis.2007.06.003","article-title":"Insight into the structural determinants for selective inhibition of matrix metalloproteinases","volume":"12","author":"Pirard","year":"2007","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113666_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/19768354.2019.1614091","volume":"23","author":"Qu","year":"2019","journal-title":"Anim. Cell Syst."},{"issue":"9","key":"10.1016\/j.ejmech.2021.113666_bib25","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/0006-2952(94)90520-7","article-title":"Utility of in\u00a0vitro drug metabolism data in predicting in\u00a0vivo metabolic clearance","volume":"47","author":"Houston","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113666_bib26","series-title":"Substituted Bis-Amide Metalloprotease Inhibitors","first-page":"131","author":"Sucholeiki","year":"2007"},{"issue":"2","key":"10.1016\/j.ejmech.2021.113666_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1139\/y99-005","article-title":"Pharmacological uses and perspectives of heavy water and deuterated compounds","volume":"77","author":"Kushner","year":"1999","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113666_bib28","first-page":"295","article-title":"Enhanced plasma concentration by selective deuteration of rofecoxib in rats","volume":"56","author":"Scheneider","year":"2006","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejmech.2021.113666_bib29","series-title":"Rappoport, Z. The Chemistry of the Cyano Group","first-page":"307","author":"Rabinovitz","year":"1970"},{"issue":"18","key":"10.1016\/j.ejmech.2021.113666_bib30","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1016\/S0040-4039(00)00410-X","article-title":"Convenient synthesis of protected primary amines from nitriles","volume":"41","author":"Caddick","year":"2000","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2021.113666_bib31","first-page":"5417","volume":"59","author":"Caddick","year":"2003","journal-title":"A\u00a0generic approach for the catalytic reduction of nitriles"},{"issue":"14","key":"10.1016\/j.ejmech.2021.113666_bib32","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1021\/jo00876a038","article-title":"A\u00a0convenient synthesis of o-and p-hyroxy substituted phenylacetonitriles and phenethylamines","volume":"41","author":"Schwartz","year":"1976","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2021.113666_bib33","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.1780400917","article-title":"Mono-iodoacetate\u2013induced experimental osteoarthritis: a dose\u2013response study of loss of mobility, morphology, and biochemistry","volume":"40","author":"Gillet","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2021.113666_bib34","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1063-4584(03)00163-8","article-title":"Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis","volume":"11","author":"Bove","year":"2003","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ejmech.2021.113666_bib35","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.joca.2004.06.004","article-title":"Detection of aggrecanase- and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration","volume":"12","author":"Janusz","year":"2004","journal-title":"Osteoarthritis Cartilage"},{"issue":"10","key":"10.1016\/j.ejmech.2021.113666_bib36","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/art.1780381017","article-title":"The incidence and natural history of knee osteoarthritis in the elderly","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"38","key":"10.1016\/j.ejmech.2021.113666_bib37","doi-asserted-by":"crossref","first-page":"27781","DOI":"10.1074\/jbc.M703286200","article-title":"Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in\u00a0vivo without joint fibroplasia side effects","volume":"282","author":"Johnson","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113666_bib38","first-page":"8","article-title":"Deuterium medicinal chemistry: a new approach to drug discovery and development","volume":"2","author":"Harbeson","year":"2014","journal-title":"Med. Chem. News"},{"issue":"9","key":"10.1016\/j.ejmech.2021.113666_bib39","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.joca.2004.06.004","article-title":"Detection of aggrecanase- and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration","volume":"12","author":"Janusz","year":"2004","journal-title":"Osteoarthritis Cartilage"},{"issue":"4","key":"10.1016\/j.ejmech.2021.113666_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/03009749309099268","article-title":"Total and free plasma and total synovial fluid piroxicam concentrations: relationship to antiinflammatory effect in patients with reactive arthritis and other arthritides","volume":"22","author":"Hundal","year":"1993","journal-title":"Scand. J. Rheumatol."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113666_bib41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/art.20762","article-title":"Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses","volume":"52","author":"Laverty","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2021.113666_bib42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-199936030-00002","article-title":"Pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid","volume":"36","author":"Day","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.ejmech.2021.113666_bib43","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.joca.2013.06.031","article-title":"Differences in structural and pain phenotypes in the sodium monoiodoacetate and meniscal transection models of osteoarthritis","volume":"21","author":"Mapp","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"10.1016\/j.ejmech.2021.113666_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.joca.2014.09.019","article-title":"Sustained efficacy of a single intra-articular dose of FX006 in a rat model of repeated localized knee arthritis","volume":"23","author":"Kumar","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"issue":"12","key":"10.1016\/j.ejmech.2021.113666_bib45","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.25002","article-title":"Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development","volume":"60","author":"Little","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2021.113666_bib46","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113666_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.31138\/mjr.27.1.21","article-title":"In\u00a0vivo study of the synovial membrane penetration index from celecoxib and etoricoxib and their impact on pain control in patients with inflammatory arthritis","volume":"27","author":"Thodoridou","year":"2016","journal-title":"Mediterr J Rheumatol"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113666_bib48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cardiores.2005.11.032","article-title":"The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors","volume":"69","author":"Peterson","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejmech.2021.113666_bib49","unstructured":"FDA, Guidance: Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis (OA), published July 15, 1999."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113666_bib50","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.joca.2011.02.018","article-title":"Summary and recommendations of the OARSI FDA osteoarthritis assessment of structural change working group","volume":"19","author":"Conaghan","year":"2011","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ejmech.2021.113666_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrrheum.2013.159","article-title":"Progress in intra-articular therapy","volume":"10","author":"Evans","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2021.113666_bib52","series-title":"Osteoarthritis: Structural Endpoints for the Development of Drugs, Devices, and Biological Products for Treatment, Draft Guidance, Clinical Guidance for Industry","author":"FDA","year":"2018"},{"key":"10.1016\/j.ejmech.2021.113666_bib53","doi-asserted-by":"crossref","first-page":"1000059","DOI":"10.1016\/j.ocarto.2020.100059","article-title":"Disease modification in osteoarthritis; pathways to drug approval","volume":"2","author":"Katz","year":"2020","journal-title":"Osteoarthritis and Cartilage Open"},{"issue":"9","key":"10.1016\/j.ejmech.2021.113666_bib54","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/0006-2952(94)90520-7","article-title":"Utility of in\u00a0vitro drug metabolism data in predicting in\u00a0vivo metabolic clearance","volume":"47","author":"Houston","year":"1994","journal-title":"Biochem. Pharmacol."},{"issue":"21","key":"10.1016\/j.ejmech.2021.113666_bib55","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1021\/jm00099a001","article-title":"A\u00a0general method for the preparation of internally quenched fluorogenic protease substrates using solid-phase peptide synthesis","volume":"35","author":"Maggiora","year":"1992","journal-title":"J.\u00a0Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113666_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.joca.2005.07.014","article-title":"Osteoarthritis cartilage histopathology: grading and staging","volume":"14","author":"Pritzker","year":"2006","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ejmech.2021.113666_bib57","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.joca.2010.05.030","article-title":"The OARSI histopathology initiative e recommendations for histological assessments of osteoarthritis in the rat","volume":"18","author":"Gerwin","year":"2010","journal-title":"Osteoarthritis Cartilage"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421005158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421005158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:28:37Z","timestamp":1759328917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421005158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":57,"alternative-id":["S0223523421005158"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113666","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113666"}}